Soreide Law Group has been contacted by investors who purchased Gemphire Therapeutics Inc. (GEMP) and experienced stock losses through the sale of the stock brokers at Laidlaw and Company. Laidlaw is listed on their website as the “Co-Manager” from the March of 2017 offering. Often, securities that are newly issued are more volatile than the more established companies, and if the investor was not looking to speculate, this could have been a highly unsuitable recommendation given to you by your broker from Laidlaw and Company.
According to Yahoo Finance, Gemphire Therapeutics Inc. (GEMP), is a clinical-stage biopharmaceutical company, focusing on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.
In March of 2017, Gemphire Therapeutics Inc. (GEMP) was trading around 12.2 and today it is trading at approximately 5.94. The 52-week change is -39.88%.
On Laidlaw and Company’s website, the following information on their company is given:”Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets.”
If you or a family member have experienced investment losses in Gemphire Therapeutics Inc. (GEMP), due to the recommendation of your broker/financial advisor at Laidlaw and Company, call Soreide Law Group for a no cost consultation with an experienced securities lawyer regarding the possible recovery of your valuable financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents clients nationwide before FINRA. We operate on a contingency fee basis, no fee if no recovery.
.
Investors potentially experienced sales practice violations by securities broker Russell Glenn Bedore [CRD: 4729849, Deerfield Beach, Florida], according to information disclosed through Financial Industry Regulatory Authority (FINRA) BrokerCheck. Bedore has been registered with LPL Financial LLC since May 14, 2026, and previously worked for J.P. Morgan Securities LLC from July 15, 2013, through May 15, […]
Investors might have sustained losses due to securities broker Matthew James Kloos [CRD: 7292988, Monroeville, Pennsylvania], based on public information on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Matthew Kloos worked for Cetera Investment Services LLC from February 21, 2024, to April 23, 2026, and previously worked for Mutual of Omaha Investor Services Inc. from August […]
Investors potentially experienced sales practice violations by securities broker Melissa Star Williams (also known as Melissa Star Bortfeld, Melissa Starr Williams, Melissa Williams Frasca) [CRD: 4298503, Spokane, Washington], according to disclosures on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Williams worked for Centaurus Financial Inc. from August 28, 2015, through March 14, 2024, before registering with […]
Phone:
Fax: 1-954-760-6553
Email: info@securitieslawyer.com